Zentiva Launches Its First Biosimilar in the European Market

Zentiva's Entry into the Biosimilars Market

On December 1, 2025, Zentiva, a prominent manufacturer of affordable and high-quality medications in Europe, announced the EU-wide launch of its first biosimilar product, marking a significant step in its strategic expansion into biologics. This development comes after receiving approval from the European Medicines Agency (EMA), positioning Zentiva as a trusted partner in healthcare dedicated to enhancing patient access to essential therapies.

Steffen Saltofte, the CEO of Zentiva, commented on the importance of this launch. He expressed that it signifies a major leap forward into the realm of biological medications. Saltofte emphasized how biosimilars align with Zentiva's mission to make high-quality treatments more accessible and affordable for individuals across Europe. This expansion portion is designed to nurture sustainable growth within one of the most dynamic sectors of the pharmaceutical industry.

The newly launched biosimilar is a monoclonal antibody specifically utilized for treating bone diseases. Following approval through the centralized procedure of the EMA, the Zentiva biosimilar will begin phased availability across various European markets starting in December.

Strategic Growth and Product Diversification

This entry into the biosimilars segment is part of Zentiva's broader strategic growth plan aimed at diversifying its product offerings beyond traditional generics. As the healthcare landscape evolves, biological medications constitute a growing share of health expenditures across Europe. The introduction of biosimilars is critical for sustaining the healthcare system and providing patients with access to modern therapies, which often come with a higher price tag.

Zentiva is structured to meet these challenges head-on. The company aims to leverage its existing capabilities in research and development, alongside its state-of-the-art manufacturing facilities and extensive supply chain, to ensure a consistent and reliable supply of biosimilar products. With more than 5,000 dedicated employees, Zentiva operates from four manufacturing plants and collaborates with a wide network of external manufacturing partners.

Commitment to Patient Health and Well-being

The mission of Zentiva extends beyond simply being a pharmaceutical provider; the company is committed to fostering health and wellness across generations. Their emphasis on the development, production, and distribution of accessible and high-quality medications ensures that over 100 million individuals across more than 30 countries can benefit from their products.

In a broader context, the push for biosimilars is seen as an essential step towards ensuring that healthcare remains sustainable and equitable. As healthcare costs continue to climb, the incorporation of biosimilars not only offers potential cost savings but also enhances patient choices in treatment options.

Zentiva aims to lead by example through this initiative, showcasing that affordable healthcare solutions are not only possible but also crucial for the future of medicine. With their ambitious growth plan on the horizon, the coming years promise exciting developments for patients and healthcare providers alike.

As Zentiva sets forth on this journey, it remains steadfast in its commitment to the people who rely on its medications daily. To learn more about Zentiva and its wide range of products, visit Zentiva's official website.